Published in Mov Disord on April 11, 2011
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain (2015) 1.50
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. Neuropsychopharmacology (2014) 0.94
Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics (2014) 0.93
Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci (2014) 0.93
Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorg Med Chem Lett (2013) 0.88
Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics. Front Endocrinol (Lausanne) (2014) 0.86
Emerging pharmacologic treatment options for fragile X syndrome. Appl Clin Genet (2015) 0.84
A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease. J Neural Transm (Vienna) (2014) 0.84
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Med (2013) 0.82
Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinsons Dis (2013) 0.82
Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments. Neuropsychiatr Dis Treat (2013) 0.82
Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. Eur J Clin Pharmacol (2013) 0.82
Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications. Cell Signal (2014) 0.81
Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease. Neurodegener Dis Manag (2012) 0.81
Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorg Med Chem Lett (2014) 0.81
Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease. Parkinsons Dis (2012) 0.81
Parkinson's disease: an update on pathogenesis and treatment. J Neurol (2013) 0.81
Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies. Front Neurol (2014) 0.81
Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics (2014) 0.80
Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates. Front Neurol (2014) 0.79
The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies. Front Neurosci (2015) 0.78
p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism. Proc Natl Acad Sci U S A (2016) 0.78
Therapeutic potential of targeting glutamate receptors in Parkinson's disease. J Neural Transm (Vienna) (2014) 0.78
Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future. Transl Neurodegener (2015) 0.77
Nondopaminergic treatments for Parkinson's disease: current and future prospects. Neurodegener Dis Manag (2016) 0.77
The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro. BMC Med Genet (2012) 0.77
mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex. CNS Neurol Disord Drug Targets (2015) 0.77
Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. Neuropsychopharmacology (2015) 0.76
Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study. Am Health Drug Benefits (2012) 0.76
N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents. Bioorg Med Chem Lett (2016) 0.75
mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias. Curr Neuropharmacol (2016) 0.75
Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors. AAPS J (2015) 0.75
Progress toward therapeutic potential for AFQ056 in Fragile X syndrome. J Exp Pharmacol (2013) 0.75
Understanding and prevention of "therapy-" induced dyskinesias. Parkinsons Dis (2012) 0.75
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med (2003) 12.71
Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med (2003) 4.95
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet (2007) 4.54
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell (2012) 4.28
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med (2011) 3.46
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology (2013) 2.99
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis (2005) 2.59
Sex and the risk of restless legs syndrome in the general population. Arch Intern Med (2004) 2.43
The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol (2008) 2.42
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int (2010) 2.27
Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology (2011) 2.17
CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem (2005) 2.08
Subthalamotomy in the treatment of Parkinson's disease: clinical aspects and mechanisms of action. J Neurosurg (2013) 1.98
Body weight in patients with Parkinson's disease. Mov Disord (2006) 1.89
Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev (2011) 1.88
The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) (2003) 1.83
Efficient generation of neural stem cell-like cells from adult human bone marrow stromal cells. J Cell Sci (2004) 1.79
Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet (2012) 1.78
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet (2008) 1.78
Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res (2010) 1.76
Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet (2011) 1.70
A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry (2006) 1.68
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord (2009) 1.62
GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest (2008) 1.60
Kick and rush: paradoxical kinesia in Parkinson disease. Neurology (2008) 1.59
Treadmill training for patients with Parkinson's disease. Cochrane Database Syst Rev (2010) 1.54
Reliability of brain CT evaluation by stroke neurologists in telemedicine. Neurology (2012) 1.54
Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain (2004) 1.54
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry (2005) 1.52
Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study. Mov Disord (2014) 1.51
Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial. Antivir Ther (2004) 1.51
Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes. Mov Disord (2012) 1.50
Oligodendrocytes enforce immune tolerance of the uninfected brain by purging the peripheral repertoire of autoreactive CD8+ T cells. Immunity (2012) 1.50
Poor effect of guideline based treatment of restless legs syndrome in clinical practice. J Neurol Neurosurg Psychiatry (2010) 1.49
Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord (2006) 1.49
Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med (2008) 1.48
Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med (2007) 1.48
SNCA: major genetic modifier of age at onset of Parkinson's disease. Mov Disord (2013) 1.48
Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl) (2001) 1.47
Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology (Berl) (2004) 1.47
Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder. Sleep Med Rev (2002) 1.46
PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology (2012) 1.44
Transcranial sonography in movement disorders. Lancet Neurol (2008) 1.44
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) (2004) 1.38
Massive axial herniation after posterior fossa infarction following vertebral artery dissection. Neurology (2009) 1.38
Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol (2009) 1.37
Adherence to antiparkinson medication in a multicenter European study. Mov Disord (2009) 1.34
Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med (2006) 1.32
Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol (2011) 1.32
The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet (2003) 1.30
The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS One (2008) 1.29
Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord (2012) 1.28
Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol (2004) 1.28
Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med (2010) 1.27
Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet (2011) 1.27
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology (2013) 1.26
Failure of adaptive self-organized criticality during epileptic seizure attacks. PLoS Comput Biol (2012) 1.25
Movement disorders on YouTube--caveat spectator. N Engl J Med (2011) 1.25
CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 1.25
HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS (2003) 1.25
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol (2010) 1.24
Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study. J Neurol (2002) 1.23
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord (2014) 1.23
Modulation of calcium-activated potassium channels induces cardiogenesis of pluripotent stem cells and enrichment of pacemaker-like cells. Circulation (2010) 1.22
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J Virol (2002) 1.20
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther (2003) 1.20
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett (2012) 1.19
A star-PEG-heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases. Biomaterials (2009) 1.19
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18
Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls. Hum Brain Mapp (2011) 1.17
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol (2006) 1.17
Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol (2008) 1.17
Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol (2011) 1.15
Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med (2007) 1.14
A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry (2009) 1.14
Comparative analysis of neuroectodermal differentiation capacity of human bone marrow stromal cells using various conversion protocols. J Neurosci Res (2006) 1.14
Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. Acta Neuropathol (2014) 1.12
Pathophysiological concepts of restless legs syndrome. Mov Disord (2007) 1.12
Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine. J Clin Sleep Med (2011) 1.12
Systematic Review of Factors Influencing Farmers' Market Use Overall and among Low-Income Populations. J Acad Nutr Diet (2016) 1.12
Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs (2004) 1.12
Decreased hippocampal volume on MRI is associated with increased extracellular glutamate in epilepsy patients. Epilepsia (2008) 1.11
Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol (2006) 1.11
The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease. Mov Disord (2011) 1.10
Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol (2009) 1.10